ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents ...

Read more

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today an...

Read more

ORYZON presents new robust Phase II iadademstat efficacy data in AML at ASH-2020

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presents new po...

Read more

ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

UPF and Hospital del Mar design a method...

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

The new method would allow for a more objective and precise classifica...

Photos Stream